• Wondering if Medtronic at around US$75.57 is a bargain or a value trap? This article walks through what the current price might really imply about the stock.
• The share price is down 3.3% over the past week, 7.7% over the last month, 21.3% year to date and 5.4% over the past year, which raises questions about whether risk has risen or value has improved.
• Recent coverage has focused on Medtronic's position as a large medical device company, including ongoing product updates and portfolio adjustments. These factors help frame investor expectations around growth and capital allocation. They also give useful context for the recent share price weakness and why sentiment may have shifted.
• In that context, Medtronic currently records a valuation score of 6 out of 6. The sections that follow compare different valuation methods and then finish with a way of thinking about value that can give an even clearer picture.

Approach 1: Medtronic Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting the company’s future cash flows and discounting them back to today’s value. It is essentially asking what those future dollars are worth in today’s terms.

For Medtronic, the model uses a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month Free Cash Flow is about $5.44b. Analyst estimates run out in the medium term, and Simply Wall St extrapolates further out, with projected Free Cash Flow of $8.64b in 2035, all expressed in $ and then discounted back to today.

Putting those cash flows together produces an estimated intrinsic value of $94.76 per share, compared with the recent share price of about $75.57. That implies the stock screens as roughly 20.3% undervalued on this DCF view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Medtronic is undervalued by 20.3%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.

Approach 2: Medtronic Price vs Earnings

For profitable companies, the P/E ratio is a useful yardstick because it compares what you pay for each share with the earnings that company is currently generating. It helps you see how much investors are willing to pay for each dollar of profit.

A “normal” or “fair” P/E usually reflects what investors expect for future growth and how much risk they see in the business. Higher expected growth or lower perceived risk can support a higher P/E, while lower growth or higher risk often point to a lower P/E.

Medtronic’s current P/E is 21.03x. This sits below the Medical Equipment industry average of 24.25x and below the peer group average of 32.56x. Simply Wall St’s Fair Ratio for Medtronic is 27.43x. This is its proprietary estimate of an appropriate P/E, based on factors such as earnings growth, profit margin, market cap, risk profile and the company’s industry.

The Fair Ratio can be more informative than a simple comparison with peers or the industry average because it attempts to reflect Medtronic’s specific characteristics rather than broad group averages. Since the Fair Ratio of 27.43x is higher than the current P/E of 21.03x, this framework suggests the stock screens as undervalued on an earnings multiple basis.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 21 top founder-led companies.

Upgrade Your Decision Making: Choose your Medtronic Narrative

Earlier it was mentioned that there is an even better way to understand valuation. This is where Narratives come in, giving you a clear story that links your view on Medtronic to a forecast and then to a fair value that you can compare with the current price.

A Narrative is simply your own explanation for why Medtronic should be worth a certain amount, tying together your expectations for revenue, earnings and margins with the factors you think matter most, such as its diversified portfolio, R&D spend or Diabetes and robotics exposure.

On Simply Wall St, Narratives sit in the Community page and are designed so any investor can plug in assumptions rather than build a full model. Investors can then see how that story translates into a Fair Value figure that can be weighed against the current share price when deciding whether the stock looks expensive or cheap.

Because Narratives update when new information such as earnings, guidance or product news is added, you can see different views side by side. For example, you might compare one Medtronic Narrative that assumes a fair value of about US$82.66 with another at about US$108, and quickly understand how different expectations on growth, margins and the P/E multiple lead to very different conclusions about the stock.

Do you think there's more to the story for Medtronic? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.